Sequence and structural analysis of kinase ATP pocket residues.

Protein kinases represent one of the largest known families of enzymes. Most kinases bind ATP and most synthetic kinase inhibitors are ATP-competitive, which makes selectivity a potential problem. However, despite the high sequence similarity in the ATP binding pocket, several groups including ours have been able to develop highly potent and selective ATP-competitive inhibitors. To systematically aid the design of specific inhibitors in our protein kinase projects, we aligned all known three-dimensional structures and all known sequences of human protein kinases. We identified a set of 38 residues that make up the ATP pocket and analyzed the variability among these residues. The most variable residues in the ATP pocket are targeted to design specificity into inhibitors in our various kinase projects.

[1]  L. Tong,et al.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.

[2]  K. Longenecker,et al.  Three-dimensional structure of mammalian casein kinase I: molecular basis for phosphate recognition. , 1996, Journal of molecular biology.

[3]  L. Toledo,et al.  The structure-based design of ATP-site directed protein kinase inhibitors. , 1999, Current medicinal chemistry.

[4]  Robert P Sheridan,et al.  A simple method for visualizing the differences between related receptor sites. , 2002, Journal of molecular graphics & modelling.

[5]  S. Hubbard,et al.  Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain , 1998, The EMBO journal.

[6]  Nader Fotouhi,et al.  Cell cycle inhibitors for the treatment of cancer , 2003 .

[7]  Bingcheng Wang,et al.  Chemometrical Classification of Ephrin Ligands and Eph Kinases Using GRID/CPCA Approach , 2003, J. Chem. Inf. Comput. Sci..

[8]  P. Cohen,et al.  Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. , 1998, Chemistry & biology.

[9]  David Komander,et al.  Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. , 2003, The Biochemical journal.

[10]  G. Bemis,et al.  Kinase inhibitors and the case for CH…O hydrogen bonds in protein–ligand binding , 2002, Proteins.

[11]  Sean R. Eddy,et al.  Profile hidden Markov models , 1998, Bioinform..

[12]  J. Kuriyan,et al.  Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. , 1999, Molecular cell.

[13]  Gerhard Klebe,et al.  Comparative Molecular Similarity Index Analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries , 1999, J. Comput. Aided Mol. Des..

[14]  K. Shokat,et al.  Inhibitor scaffolds as new allele specific kinase substrates. , 2002, Journal of the American Chemical Society.

[15]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[16]  L. Toledo,et al.  Structures of staurosporine bound to CDK2 and cAPK--new tools for structure-based design of protein kinase inhibitors. , 1997, Structure.

[17]  Yanli Wang,et al.  Molecular determinants for ATP-binding in proteins: a data mining and quantum chemical analysis. , 2004, Journal of molecular biology.

[18]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[19]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[20]  P. Furet,et al.  4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. , 1996, Journal of medicinal chemistry.

[21]  M. Bower,et al.  Structural Basis for Chk1 Inhibition by UCN-01* , 2002, The Journal of Biological Chemistry.

[22]  E. Goldsmith,et al.  Structural basis of inhibitor selectivity in MAP kinases. , 1998, Structure.

[23]  L Xue,et al.  Molecular scaffold-based design and comparison of combinatorial libraries focused on the ATP-binding site of protein kinases. , 1999, Journal of molecular graphics & modelling.

[24]  Gabriele Cruciani,et al.  Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. , 2002, Journal of medicinal chemistry.

[25]  W. Denny,et al.  Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding. , 1997, Journal of medicinal chemistry.

[26]  K. Denessiouk,et al.  When fold is not important: A common structural framework for adenine and AMP binding in 12 unrelated protein families , 2000, Proteins.

[27]  R. Cramer,et al.  Recent advances in comparative molecular field analysis (CoMFA). , 1989, Progress in clinical and biological research.

[28]  L. Toledo,et al.  Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. , 2000, Structure.

[29]  Ramaswamy Nilakantan,et al.  Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2) , 2003 .

[30]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[31]  Mika A. Kastenholz,et al.  GRID/CPCA: a new computational tool to design selective ligands. , 2000, Journal of medicinal chemistry.

[32]  M. Lamers,et al.  Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. , 1999, Journal of molecular biology.

[33]  G Klebe,et al.  Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.